https://perset-farma.com/producto/imjudo-tremelimumab/
IMJUDO (Tremelimumab) - PersetFarma
Nov 4, 2025 - IMJUDO está indicado para el tratamiento de primera línea de adultos con carcinoma hepatocelular (CHC) avanzado o irresecable.
imjudotremelimumab
https://ncoda.org/resource/pqi-tremelimumab-actl-imjudo-patient-management/
PQI: Tremelimumab-actl (Imjudo®) Patient Management - NCODA
Mar 27, 2025 - Empowering the Medical Oncology Pharmacy Practic
pqitremelimumabactlpatientmanagement
https://air.unimi.it/handle/2434/1239935
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular...
reproduciblesafetyefficacydurvalumabwithout
https://www.astrazeneca.se/media/pressmeddelanden/svenska_pressmeddelanden/2021/imfinzi-plus-tremelimumab-significantly-improved-overall-surviva.html
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in...
phase iii trialoverall survivalimfinziplustremelimumab
https://www.chemoexperts.com/fr/tremelimumab-imjudo-durvalumab-imfinzi-carboplatin-pemetrexed-nsclc.html
Tremelimumab (Imjudo®) + Durvalumab (Imfinzi®) + Carboplatin + Pemetrexed dans le traitement du...
Apr 3, 2024 - Le traitement associant le Tremelimumab (Imjudo®), le Durvalumab (Imfinzi®), le Carboplatin et le Pemetrexed comporte des informations que les patients doivent...
tremelimumabdurvalumabcarboplatinpemetrexeddans
https://pure.skku.edu/en/publications/durvalumab-with-or-without-tremelimumab-plus-platinumetoposide-ve/
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone...
durvalumabwithouttremelimumabplusversus
https://www.astrazeneca.com/media-centre/press-releases/2022/tremelimumab-us-priority-review-imfinzi-combo.html
Tremelimumab US Priority Review for Imfinzi combo
STRIDE regimen of a single priming dose of tremelimumab added to Imfinzi is the first dual immune checkpoint blockade regimen to improve overall survival in a...
priority reviewtremelimumabimfinzicombo